Advertisement

Hematopoietic Growth Factors

  • Anurag K. Agrawal
  • Jeffrey D. HordEmail author
Chapter
Part of the Pediatric Oncology book series (PEDIATRICO)

Abstract

Several recombinant human hematopoietic growth factors are approved and in clinical use but not all are approved for use in children with cancer. Here we review the evidence-based guidelines for neutrophil stimulating factors granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as well as evidence regarding erythropoietins and platelet growth factors interleukin-11 (IL-11) and thrombopoietin (TPO)-receptor agonists. Among these hematopoietic growth factors, only G-CSF and GM-CSF are approved in children with cancer; we review the evidence regarding their use in different clinical scenarios as well as the appropriate timing and dose of therapy. Evidence regarding the current status of the other hematopoietic cytokines in regard to pediatric oncology patients is also reviewed.

Keywords

Febrile Neutropenia Immune Thrombocytopenic Purpura Darbepoetin Alfa Hematopoietic Growth Factor Pediatric Oncology Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 Update of EORTC Guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 47:8–32PubMedGoogle Scholar
  2. Aapro M, Jeklmann W, Constantinescu SN, Leyland-Jones B (2012) Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 106:1249–1258PubMedCentralPubMedGoogle Scholar
  3. Abdelrazik N, Fouda M (2007) Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. Hematology 12:533–541PubMedGoogle Scholar
  4. Alonzo TA, Kobrinsky NL, Aledo A et al (2002) Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol 24:627–635PubMedGoogle Scholar
  5. Andemariam B, Psaila B, Bussel JB (2007) Novel thrombopoietic agents. Hematology Am Soc Hematol Educ Program 106–113Google Scholar
  6. André N, Kababri ME, Bertrand P et al (2007) Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 18:277–281PubMedGoogle Scholar
  7. Angiolillo AL, Davenport V, Bonilla MA et al (2005) A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children’s Oncology Group experience. Clin Cancer Res 11:2644–2650PubMedGoogle Scholar
  8. Antman KS, Griffin JD, Elias A et al (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593–598PubMedGoogle Scholar
  9. Basser RL, Rasko JE, Clarke K et al (1997) Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89:3118–3128PubMedGoogle Scholar
  10. Basser RL, Underhill C, Davis I et al (2000) Enhancement on platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 18:2852–2861PubMedGoogle Scholar
  11. Basser RL, O’Flaherty E, Green M et al (2002) Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99:2599–2602PubMedGoogle Scholar
  12. Batra S, Perelman N, Luck LR et al (2003) Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477–1487PubMedGoogle Scholar
  13. Bennett CL, Silver SM, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914–924PubMedGoogle Scholar
  14. Bhatia M, Davenport V, Cairo MS (2007) The role of interleukins-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymphoma 48:9–15PubMedGoogle Scholar
  15. Blumer J, Berg S, Adamson PC et al (2007) Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. Pediatr Blood Cancer 49:687–693PubMedGoogle Scholar
  16. Bohlius J, Wilson J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714PubMedGoogle Scholar
  17. Bohlius J, Schmidlin K, Brillant C et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 373:1532–1542PubMedGoogle Scholar
  18. Bohlius J, Schmidlin K, Brillant C et al (2010) Erythropoietin or darbepoetin for patients with cancer—meta-analysis based on individual patient data. Cochrane Database Syst Rev (3):CD007303Google Scholar
  19. Bokemeyer C (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201–2216PubMedGoogle Scholar
  20. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15PubMedGoogle Scholar
  21. Borinstein SC, Pollard J, Winter L, Hawkins DS (2009) Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatr Blood Cancer 53:375–378PubMedGoogle Scholar
  22. Bronchud MH, Howell A, Crowther D et al (1989) The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121–125PubMedCentralPubMedGoogle Scholar
  23. Broudy VC, Lin NL, Kaushansky K (1995) Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719–1726PubMedGoogle Scholar
  24. Bussel JB, Kuter DJ, George JN et al (2006) AMG 531, a thrombopoiesis-stimulating protein for chronic ITP. N Engl J Med 355:1672–1681PubMedGoogle Scholar
  25. Bussel JB, Cheng G, Saleh MN et al (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237–2247PubMedGoogle Scholar
  26. Bussel JB, Kuter DJ, Pullarkat V et al (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113:2161–2171PubMedGoogle Scholar
  27. Bussel JB, Buchanan GR, Nugent DJ et al (2011) A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 118:28–36PubMedGoogle Scholar
  28. Büyükpamukçu M, Varan A, Kutluk T et al (2002) Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med Pediatr Oncol 39:455–458PubMedGoogle Scholar
  29. Cairo MS, Shen V, Krailo MD et al (2001) Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol 23:30–38PubMedGoogle Scholar
  30. Cairo MS, Davenport V, Bessmertny O et al (2004) Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol 128:49–58Google Scholar
  31. Ciernik IF, Schanz U, Gmür J (1999) Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant 24:147–151PubMedGoogle Scholar
  32. Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214PubMedGoogle Scholar
  33. Çorapcioglu F, Aksu G, Basar E et al (2008) Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer therapy. Pediatr Hematol Oncol 25:509–521PubMedGoogle Scholar
  34. Cripe LD, Rader K, Tallman MS et al (2006) Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. Leuk Res 30:823–827PubMedGoogle Scholar
  35. Csáki C, Ferencz T, Schuler D et al (1998) Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumors. Eur J Cancer 34:364–367PubMedGoogle Scholar
  36. Demetri GD (2001) Targeted approaches for the treatment of thrombocytopenia. Oncologist 6:15–23PubMedGoogle Scholar
  37. Djulbegovic B, Frohlich A, Bennett CL (2005) Acting on imperfect evidence: how much regret are we ready to accept? J Clin Oncol 23:6822–6825PubMedGoogle Scholar
  38. Du X, Williams DA (1997) Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89:3897–3908PubMedGoogle Scholar
  39. Dubois RW, Pinto LA, Bernal M et al (2004) Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature. Support Care Cancer 2:34–41Google Scholar
  40. Durmaz O, Demirkaya M, Sevinir B (2011) Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. Pediatr Hematol Oncol 28:461–468PubMedGoogle Scholar
  41. Eguchi K, Shinkai T, Sasaki Y et al (1990) Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy in patients with advanced lung cancer. Jpn J Cancer Res 81:1168–1174PubMedGoogle Scholar
  42. Elafy MS, Abdelmaksoud AA, Eltonbary KY (2011) Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol 90:1341–1344Google Scholar
  43. ESMO Guidelines Working Group, Greil R, Psenak O (2007) Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol 18:ii89–ii91Google Scholar
  44. Fanucchi M, Glapsy J, Crawford J et al (1997) Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404–409PubMedGoogle Scholar
  45. Farese AM, Smith WG, Giri JG et al (2001) Promegapoietin-1a, an engineered chimeric IL-3 and Mpl-L receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedules following radiation-induced myelosuppression in nonhuman primates. Stem Cells 19:329–338PubMedGoogle Scholar
  46. Fernandez MC, Krailo MD, Gerbing RR et al (2000) A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. Cancer 88:2838–2844PubMedGoogle Scholar
  47. Feusner J (2009) Guidelines for Epo use in children with cancer. Pediatr Blood Cancer 53:308–309PubMedGoogle Scholar
  48. Feusner J, Hastings C (2002) Recombinant human erythropoietin in pediatric oncology: a review. Med Pediatr Oncol 39:463–468PubMedGoogle Scholar
  49. Fox E, Widemann BC, Hawkins DS et al (2009) Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 15:7361–7367PubMedCentralPubMedGoogle Scholar
  50. Galliford JW, Malasana R, Farrington K (2005) Switching from subcutaneous to intravenous erythropoietin α in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 20:1956–1962PubMedGoogle Scholar
  51. Gernsheimer T (2008) The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 219–226Google Scholar
  52. Giles FJ, Kantarijian HM, Cortes JE et al (2005) Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29:649–652PubMedGoogle Scholar
  53. Glasby J, Crawford J, Vansteenkiste J et al (2010) Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 102:301–315Google Scholar
  54. Glaspy J, Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 13:461–473; discussion 477–478, 483–488PubMedGoogle Scholar
  55. Gordon MS, McCaskill-Stevens WJ, Battiato LA et al (1996) A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615–3624PubMedGoogle Scholar
  56. Gurion R, Belnik-Plitman Y, Gafter-Gvili A et al (2012) Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev (6):CD008238Google Scholar
  57. Guyatt G, Gutterman D, Baumann MH et al (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129:174–181PubMedGoogle Scholar
  58. Hägglund H, Ringdén O, Oman S et al (1999) A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 24:831–836PubMedGoogle Scholar
  59. Henke M, Laszig R, Rübe C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260PubMedGoogle Scholar
  60. Hofmann WK, Seipelt G, Langerhan S et al (2002) Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol 81:570–574PubMedGoogle Scholar
  61. Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731PubMedGoogle Scholar
  62. Honkoop AH, Hoekman K, Wagstaff J et al (1996) Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously. Br J Cancer 74:1132–1136PubMedCentralPubMedGoogle Scholar
  63. Isaacs C, Robert NJ, Bailey FA et al (1997) Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15:3368–3377PubMedGoogle Scholar
  64. Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72:449–489PubMedGoogle Scholar
  65. Jenkins JM, Williams D, Deng Y et al (2007) Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109:4739–4741PubMedGoogle Scholar
  66. Jones CA, Shaw PJ, Stevens MM (1995) Use of granulocyte colony stimulating factor to reduce the toxicity of super-VAC chemotherapy in advanced solid tumours in childhood. Med Pediatr Oncol 25:84–89PubMedGoogle Scholar
  67. Jones SE, Khandelwal P, McIntyre K et al (1999) Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. J Clin Oncol 17:3025–3032PubMedGoogle Scholar
  68. Kaneko T, Takaku F, Ogawa M (1991) Outline of clinical studies on recombinant human granulocyte colony stimulating factor (KRN 8601) in Japan. Tokai J Exp Clin Med 16:51–61PubMedGoogle Scholar
  69. Kaufman JS, Reda DJ, Fye CL et al (1998) Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339:578–583PubMedGoogle Scholar
  70. Kaushansky K (1998) Thrombopoietin. N Engl J Med 339:746–754PubMedGoogle Scholar
  71. Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339–3347PubMedCentralPubMedGoogle Scholar
  72. Kaushansky K, Lok K, Holly RD et al (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568–571PubMedGoogle Scholar
  73. Kawakami M, Tsutsumi M, Kumakawa T et al (1990) Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 76:1962–1964PubMedGoogle Scholar
  74. Krantz SB (1991) Erythropoietin. Blood 77:419–434PubMedGoogle Scholar
  75. Kubota M, Akiyama Y, Mikawa H, Tsutsui T (1995) Comparative effect of 100 versus 250 micrograms/m2/day of G-CSF in pediatric patients with neutropenia induced by chemotherapy. Pediatr Hematol Oncol 12:393–397PubMedGoogle Scholar
  76. Kushner BH, LaQuaglia MP, Bonilla MA et al (1994) Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607–2613PubMedGoogle Scholar
  77. Kushner BH, Meyers PA, Gerald WL et al (1995) Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol 13:2796–2804PubMedGoogle Scholar
  78. Kushner BH, Heller G, Kramer K et al (2000) Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer 89:2122–2130PubMedGoogle Scholar
  79. Kuter DJ (2007) New thrombopoietic growth factors. Blood 109:4607–4616PubMedCentralPubMedGoogle Scholar
  80. Kuter DJ, Beeler DL, Rosenberg RD (1994) The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 91:11104–11108PubMedCentralPubMedGoogle Scholar
  81. Kuter DJ, Cebon J, Harker LA et al (1999) Platelet growth factors: potential impact on transfusion medicine. Transfusion 39:321–332PubMedGoogle Scholar
  82. Kuter DJ, Bussel JB, Lyons RM et al (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenia purpura: a double-blind randomized controlled trial. Lancet 371:395–403PubMedGoogle Scholar
  83. Kuter DJ, Bussel JB, Newland A et al (2013) Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 161:411–423PubMedGoogle Scholar
  84. Kwak LW, Halpern J, Olshen RA et al (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977PubMedGoogle Scholar
  85. Layton JE, Hockman H, Sheridan WP et al (1989) Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74:1303–1307PubMedGoogle Scholar
  86. Lee KH, Lee JH, Choi SJ et al (1999) Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Bone Marrow Transplant 24:591–599PubMedGoogle Scholar
  87. Lehrnbecher T, Welte K (2002) Haematopoietic growth factors in children with neutropenia. Br J Haematol 116:28–56PubMedGoogle Scholar
  88. Lehrnbecher T, Zimmermann M, Reinhardt D et al (2007) Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood 109:936–943PubMedGoogle Scholar
  89. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460PubMedGoogle Scholar
  90. Li J, Yang C, Xia Y et al (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248PubMedGoogle Scholar
  91. Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 327:28–35PubMedGoogle Scholar
  92. Lydaki E, Bolonaki E, Staikaki E et al (1995) Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies. Pediatr Hematol Oncol 12:551–558PubMedGoogle Scholar
  93. Marec-Berard P, Chastagner P, Kassab-Chahmi D et al (2009) 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer 53:7–12PubMedGoogle Scholar
  94. Masuda S, Nagao M, Sasaki R (1999) Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 70:1–6PubMedGoogle Scholar
  95. Meropol NJ, Miller LL, Korn EL et al (1992) Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 84:1201–1203PubMedGoogle Scholar
  96. Michel G, Landman-Parker J, Auclerc MF et al (2000) Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 18:1517–1524PubMedGoogle Scholar
  97. Michon JM, Hartmann O, Bouffet E et al (1998) An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer 34:1063–1069PubMedGoogle Scholar
  98. Milano-Bausset E, Gaudart J, Rome A et al (2009) Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF. Clin Ther 31:2388–2395PubMedGoogle Scholar
  99. Miller LL, Korn EL, Stevens DS et al (1999) Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood 93:3250–3258PubMedGoogle Scholar
  100. Mitchell PL, Morland B, Stevens MC et al (1997) Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 15:1163–1170PubMedGoogle Scholar
  101. Musashi M, Yang YC, Paul SR et al (1991) Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci U S A 88:765–769PubMedCentralPubMedGoogle Scholar
  102. Muskowitz CH, Hamlin PA, Gabrilove J et al (2007) Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol 18:1842–1850Google Scholar
  103. O’Shaughnessy JA, Tolcher A, Riseberg D et al (1996) Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood 87:2205–2211PubMedGoogle Scholar
  104. Orazi A, Copper RJ, Tong J et al (1996) Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol 24:1289–1297PubMedGoogle Scholar
  105. Ozkaynak MF, Krailo M, Chen Z et al (2005) Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 45:274–280PubMedGoogle Scholar
  106. Porter JC, Leahey A, Polise K et al (1996) Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr 129:656–660PubMedGoogle Scholar
  107. Rahiala J, Perkkio M, Riikonen P (1999) Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer. Med Pediatr Oncol 32:326–330PubMedGoogle Scholar
  108. Razzouk BI, Hord JD, Hockenberry M et al (2006) Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 24:3583–3589PubMedGoogle Scholar
  109. Riikonen P, Saarinen UM, Mäkipernaa A et al (1994) Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 13:197–202PubMedGoogle Scholar
  110. Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28:4996–5010PubMedGoogle Scholar
  111. Saarinen-Pihkala UM, Lanning M, Perkkiö M et al (2000) Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med Pediatr Oncol 34:319–327PubMedGoogle Scholar
  112. Sartelet H, Fabre M, Castaing M et al (2007) Expression of erythropoietin and its receptor in neuroblastomas. Cancer 110:1096–1105PubMedGoogle Scholar
  113. Sasse EC, Sasse AD, Brandalise SR et al (2005) Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev (3):CD004139Google Scholar
  114. Schaison G, Eden OB, Henze G et al (1998) Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr 157:955–966PubMedGoogle Scholar
  115. Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21:v244–v247PubMedGoogle Scholar
  116. Shankar AG (2008) The role of recombinant erythropoietin in childhood cancer. Oncologist 13:157–166PubMedGoogle Scholar
  117. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendation for the use of white blood cell growth factors: an evidence–based clinical practice guideline. J Clin Oncol 24:3187–3205PubMedGoogle Scholar
  118. Spunt SL, Irving H, Frost J et al (2010) Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 28:1329–1336PubMedCentralPubMedGoogle Scholar
  119. Stute N, Furman WL, Schell M et al (1995) Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J Pharm Sci 84:824–828PubMedGoogle Scholar
  120. Sung L, Nathan PC, Lange B et al (2004) Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 22:3350–3356PubMedGoogle Scholar
  121. Sung L, Aplenc R, Alonzo TA et al (2013) Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children’s Oncology Group. Blood 121:3573–3577PubMedCentralPubMedGoogle Scholar
  122. Takeshita A, Shinjo K, Higuchi M et al (2000) Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group. Br J Haematol 108:55–63PubMedGoogle Scholar
  123. te Poele E, Kamps W, Tamminga R et al (2005) Pegfilgrastim in pediatric cancer patients. J Pediatr Hematol Oncol 27:627–629Google Scholar
  124. Tepler I, Elias L, Smith JW et al (1996) A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607–3614PubMedGoogle Scholar
  125. Teramura M, Kobayashi S, Hoshino S et al (1992) Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327–331PubMedGoogle Scholar
  126. Usuki K, Urabe A, Ikeda Y et al (2007) A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia. Int J Hematol 85:59–69PubMedGoogle Scholar
  127. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C et al (2000) Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 132:364–368PubMedGoogle Scholar
  128. Vadhan-Raj S, Patel S, Bueso-Ramos C et al (2003) Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21:3158–3167PubMedGoogle Scholar
  129. Vadhan-Raj S, Cohen V, Bueso-Ramos C (2005) Thrombopoietic growth factors and cytokines. Curr Hematol Rep 4:137–144PubMedGoogle Scholar
  130. Vercaigne LM, Collins DM, Penner SB (2005) Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population. J Clin Pharmacol 45:895–900PubMedGoogle Scholar
  131. Vredenburgh JJ, Hussein A, Fisher D et al (1998) A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant 4:134–141PubMedGoogle Scholar
  132. Wagner L, Billups CA, Furman WL et al (2004) Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol 22:1886–1893PubMedGoogle Scholar
  133. Wendelin G, Lackner H, Schwinger W et al (2005) Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing Sarcoma. J Pediatr Hematol Oncol 27:449–451PubMedGoogle Scholar
  134. White L, McCowage G, Kannourakis G et al (1994) Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol 12:522–531PubMedGoogle Scholar
  135. Wittman B, Horan J, Lyman G (2006) Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev 32:289–303PubMedGoogle Scholar
  136. Womer RB, West DC, Krailo MD et al (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154PubMedCentralPubMedGoogle Scholar
  137. Woods WG, Kobirnsky N, Buckley J et al (1993) Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Children’s Cancer Group pilot study. J Clin Oncol 11:1448–1457PubMedGoogle Scholar
  138. Yasuda Y, Fujita Y, Matsuo T et al (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021–1029PubMedGoogle Scholar
  139. Yilmaz D, Çetingül N, Kantar M et al (2004) A single institutional experience: is epoetin alpha effective in anemic children with cancer? Pediatr Hematol Oncol 21:1–8PubMedGoogle Scholar
  140. Zamboni WC, Stewart CE (2002) An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy 22:133S–140SPubMedGoogle Scholar
  141. Zeuner A, Signore M, Martinetti D et al (2007) Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res 67:4767–4773PubMedGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Hematology/OncologyChildren’s Hospital and Research Center OaklandOaklandUSA
  2. 2.Pediatric Hematology/OncologyChildren’s Hospital Medical Center of AkronAkronUSA

Personalised recommendations